Literature DB >> 25189721

Hereditary erythrocytosis, thrombocytosis and neutrophilia.

Wan-Jen Hong1, Jason Gotlib2.   

Abstract

Hereditary erythrocytosis, thrombocytosis, and neutrophilia are rare inherited syndromes which exhibit Mendelian inheritance. Some patients with primary hereditary erythrocytosis exhibit a mutation in the erythropoietin receptor (EPOR) which is associated with low serum erythropoietin (EPO) levels. Secondary congenital erythrocytosis may be characterized by normal or high serum EPO levels, and is related to high oxygen affinity haemoglobin variants, mutation of the enzyme biphosphoglycerate mutase (BPGM), or defects in components of the oxygen-sensing pathway. Hereditary thrombocytosis was first linked to mutations in genes encoding thrombopoietin (THPO) or the thrombopoietin receptor, MPL. More recently, germline mutations in JAK2, distinct from JAK2 V617F, and mutation of the gelsolin gene, were uncovered in several pedigrees of hereditary thrombocytosis. Hereditary neutrophilia has been described in one family with an activating germline mutation in CSF3R. The mutational basis for most hereditary myeloproliferative disorders has yet to be identified.
Copyright © 2014. Published by Elsevier Ltd.

Entities:  

Keywords:  JAK2; MPL; TPO; familial; hereditary erythrocytosis; neutrophilia; polycythaemia; thrombocytosis

Mesh:

Substances:

Year:  2014        PMID: 25189721     DOI: 10.1016/j.beha.2014.07.002

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  7 in total

1.  Germline JAK2 L611S mutation in a child with thrombocytosis.

Authors:  Bernard Aral; Martine Courtois; Sylviane Ragot; Valentin Bourgeois; Elodie Bottolier-Lemallaz; Claire Briandet; François Girodon
Journal:  Haematologica       Date:  2018-03-22       Impact factor: 9.941

Review 2.  Genomic landscape of megakaryopoiesis and platelet function defects.

Authors:  Elisa Bianchi; Ruggiero Norfo; Valentina Pennucci; Roberta Zini; Rossella Manfredini
Journal:  Blood       Date:  2016-01-19       Impact factor: 22.113

Review 3.  Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.

Authors:  Elisa Rumi; Mario Cazzola
Journal:  Blood       Date:  2016-12-27       Impact factor: 22.113

4.  Screening of Potential Biomarkers in the Peripheral Serum for Steroid-Induced Osteonecrosis of the Femoral Head Based on WGCNA and Machine Learning Algorithms.

Authors:  Jian Zhang; Chi Huang; Zehan Liu; Shuai Ren; Zilong Shen; Kecheng Han; Weiguang Xin; Guanyi He; Jianyu Liu
Journal:  Dis Markers       Date:  2022-02-10       Impact factor: 3.434

5.  Unexplained Hematocrit Increase after Therapeutic Phlebotomy in a Patient with Marked Erythrocytosis.

Authors:  Rushad Machhi; Ashley M Cunningham; Kenneth Hennrick; Karen A Schaser; Eliot C Williams; William Nicholas Rose
Journal:  Case Rep Hematol       Date:  2022-08-11

Review 6.  JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.

Authors:  William Vainchenker; Emilie Leroy; Laure Gilles; Caroline Marty; Isabelle Plo; Stefan N Constantinescu
Journal:  F1000Res       Date:  2018-01-17

7.  Genetic variants associated with platelet count are predictive of human disease and physiological markers.

Authors:  Evgenia Mikaelsdottir; Gudmar Thorleifsson; Lilja Stefansdottir; Gisli Halldorsson; Jon K Sigurdsson; Sigrun H Lund; Vinicius Tragante; Pall Melsted; Solvi Rognvaldsson; Kristjan Norland; Anna Helgadottir; Magnus K Magnusson; Gunnar B Ragnarsson; Sigurdur Y Kristinsson; Sigrun Reykdal; Brynjar Vidarsson; Ingibjorg J Gudmundsdottir; Isleifur Olafsson; Pall T Onundarson; Olof Sigurdardottir; Emil L Sigurdsson; Gerdur Grondal; Arni J Geirsson; Gudmundur Geirsson; Julius Gudmundsson; Hilma Holm; Saedis Saevarsdottir; Ingileif Jonsdottir; Gudmundur Thorgeirsson; Daniel F Gudbjartsson; Unnur Thorsteinsdottir; Thorunn Rafnar; Kari Stefansson
Journal:  Commun Biol       Date:  2021-09-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.